Cellular therapies are a group of advanced treatments that use living cells to treat cancer and other serious diseases. Instead of relying only on medicines that act on the body from outside, cellular therapies use specially selected, modified, or transplanted cells to restore healthy function or help the immune system recognise and attack abnormal cells.

In hematology and oncology, cellular therapies have become an important area of treatment, particularly for selected blood cancers. CAR-T cell therapy is one of the best-known examples, while other approaches involving natural killer (NK) cells, T cells, and stem cells continue to develop.

What Are Cellular Therapies?

Cellular therapy involves using living cells as part of a treatment.

The cells may be:

• Collected from the patient

• Collected from a donor

• Modified in a laboratory

• Expanded to increase their number

• Selected based on specific characteristics

• Transplanted to restore the blood-forming system

Depending on the therapy, cells may be used to replace damaged blood-forming cells, strengthen an immune response, or directly target cancer cells.

Cellular Therapies in Hematology

Cellular therapies are particularly relevant to hematological malignancies because blood and immune cells can be collected, manipulated, and returned to the patient.

Some important approaches include:

CAR-T Cell Therapy

CAR-T cell therapy is a form of immunotherapy in which a patient's T cells are collected from the blood and genetically modified in a laboratory.

The modified cells are given a new receptor called a chimeric antigen receptor (CAR). This receptor helps the T cells recognise specific proteins on cancer cells.

The cells are then multiplied in the laboratory and infused back into the patient. Once inside the body, they can recognise and attack cells carrying the target antigen.

CAR-T therapies are currently used for selected blood cancers, including certain leukemias, lymphomas, and multiple myeloma. The exact indications depend on the specific cellular therapy and regulatory approval.

Natural Killer (NK) Cell Therapies

Natural killer cells are immune cells that can recognise and destroy certain abnormal or infected cells.

Researchers are studying both donor-derived NK cells and genetically modified CAR-NK cells as potential treatments for hematological malignancies. Many of these approaches remain under clinical investigation.

T-Cell Therapies

Beyond CAR-T therapy, researchers are developing other approaches that use T cells to recognise and attack cancer cells.

These include different forms of adoptive T-cell therapy and genetically engineered T-cell approaches. Some are approved for specific conditions, while others remain under clinical investigation.

Hematopoietic Stem Cell Transplantation

Stem cell transplantation is another major cellular therapy used in hematology.

Healthy blood-forming stem cells can be collected from the patient or a donor and infused after appropriate conditioning treatment. The transplanted cells can rebuild the blood-forming and immune systems.

Allogeneic stem cell transplantation can also produce a graft-versus-leukemia effect, where donor immune cells recognise and attack remaining abnormal blood cells.

How Does CAR-T Cell Therapy Work?

1. Patient Evaluation

The patient is assessed to determine whether the specific disease and clinical situation are appropriate for CAR-T therapy.

2. T-Cell Collection

T cells are collected from the patient's blood using a process called apheresis.

3. Genetic Modification

The collected T cells are modified in a specialised laboratory so they express a CAR designed to recognise a particular cancer-associated antigen.

4. Cell Expansion

The modified cells are multiplied in the laboratory to produce the required treatment dose.

This manufacturing process can take several weeks, depending on the specific therapy.

5. Conditioning Treatment

Before receiving the modified cells, patients generally receive lymphodepleting chemotherapy to prepare the body for the cellular therapy.

6. CAR-T Cell Infusion

The engineered cells are infused back into the patient's bloodstream.

7. Monitoring and Follow-Up

The patient is closely monitored after infusion for treatment response and possible complications.

What Conditions Can Cellular Therapies Treat?

Cellular therapies are used or being investigated for a range of diseases.

In hematology, they may have a role in selected patients with:

• Acute lymphoblastic leukemia

• Certain non-Hodgkin lymphomas

• Multiple myeloma

• Other hematological malignancies in clinical trials

The suitability of a cellular therapy depends on the exact diagnosis, disease stage, previous treatments, biomarker or antigen expression, and regulatory indications for the particular therapy.

Potential Benefits of Cellular Therapies

Cellular therapies offer a fundamentally different approach to cancer treatment.

Instead of relying exclusively on conventional medicines, some cellular therapies can harness or modify the patient's own immune cells to recognise cancer.

Potential benefits may include:

• Highly targeted immune activity

• Treatment options for selected relapsed or refractory cancers

• Long-term persistence of therapeutic cells in some patients

• Potential for durable responses in selected diseases

However, cellular therapies do not work for every patient, and their benefits vary according to the disease and individual circumstances.

What Are the Risks of Cellular Therapy?

Cellular therapies can cause significant side effects and require specialised monitoring.

Cytokine Release Syndrome

One important complication of CAR-T therapy is cytokine release syndrome (CRS).

It occurs when activated immune cells release large amounts of cytokines, which can cause symptoms such as:

• Fever

• Low blood pressure

• Rapid heartbeat

• Headache

• Nausea

• Breathing difficulties

The severity can range from mild to potentially life-threatening.

Neurological Side Effects

Some patients receiving CAR-T therapy can develop neurological complications. These may include confusion, difficulty speaking, tremors, or other changes in neurological function.

Close monitoring allows the treatment team to identify and manage these complications promptly.

Low Blood Counts and Infections

Patients may experience low blood counts and increased susceptibility to infections, particularly around the period of lymphodepleting chemotherapy and cellular therapy.

Other risks vary according to the specific cellular therapy being used.

Cellular Therapy and Personalised Medicine

One of the important features of cellular therapy is its potential for personalised treatment.

CAR-T therapy, for example, uses a patient's own T cells and modifies them to recognise a specific target.

Before treatment, doctors may therefore evaluate:

• Exact cancer subtype

• Disease status

• Target antigen expression

• Previous treatments

• Overall health

• Organ function

• Infection status

This information helps determine whether a particular cellular therapy is appropriate.

Cellular Therapies and Clinical Research

The field of cellular therapy continues to evolve rapidly.

Researchers are studying:

• CAR-NK cells

• Next-generation CAR-T cells

• Donor-derived cellular therapies

• Genetically engineered immune cells

• T-cell receptor therapies

• Combination cellular therapies

• Cellular therapies for diseases that currently have limited treatment options

Some of these approaches are still experimental and should only be considered within appropriately regulated clinical trials or approved treatment pathways.

When May Cellular Therapy Be Considered?

Cellular therapy may be considered when a patient has a disease for which an appropriate cellular treatment is available and the patient meets the relevant clinical criteria.

For some therapies, treatment is considered after other treatments have failed or the disease has returned. In other situations, cellular therapy may be incorporated earlier depending on the specific disease and approved indication.

A specialist hematology or cellular therapy team evaluates each patient individually.